245 / 1578
/
Medical Oncology
Radio-Oncology
Cetuximab
Panatimumab
Erlotinib
Trastuzumab
Lapatinib
Bevacizumab
Axatinib
Sorafenib
Sunitinib
Pazopanib
Ipilimumab
Vandetanib
Colorectal
Breast
Pancreas
NSCLC
Glioblastoma
Kidney
GIST
Thyroid
Head & Neck
Cetuximab
Head & Neck
Approved targeted drugs
ESTRO SBRT COURSE 2017 - Matthias Guckenberger
17
07.09.17
/
Gefitinib
in mutant EGFR
Maemondo NEJM 2010
Crizotinib
in ALK positive
Shaw NEJM 2013
Brahmer NEJM 2015
Nivolumab
in unselected patients
Ø
Substantial and clinically relevant improvement
Ø
Still: 60 – 80% develop progressive disease after 12 months
Progression under targeted
systemic
ESTRO SBRT COURSE 2017 - Matthias Guckenberger
18
07.09.17